Inotropes - Pharmacology | Varsity Tutors

SECTION 1

Historical Context & Motivation

The quest to augment the force of cardiac contraction is arguably one of the oldest pursuits in pharmacology. Long before clinicians understood the molecular basis of myocardial contractility, healers in ancient Egypt and Rome observed that extracts of the foxglove plant could alter heart rhythm and vigor. The modern era of inotropic therapy began in the eighteenth century when William Withering systematically documented the cardiovascular effects of Digitalis purpurea, establishing a bridge between herbal tradition and evidence-based medicine. Since then, the development of inotropes has tracked closely with advances in cardiac physiology, receptor biology, and critical-care medicine, culminating in the diverse pharmacological armamentarium available today.

1785 • Withering & Digitalis

William Withering published An Account of the Foxglove, documenting digitalis's ability to relieve 'dropsy' (edema from heart failure) and establishing the first systematic use of a cardiac glycoside.

1948 • Ahlquist's Receptor Classification

Raymond Ahlquist proposed the distinction between α- and β-adrenergic receptors, laying the groundwork for understanding how catecholamines such as epinephrine and norepinephrine modulate cardiac contractility through β₁-receptor stimulation.

1975 • Milrinone & PDE Inhibitors

Phosphodiesterase-3 (PDE-3) inhibitors emerged as a new class of inotropes, offering an alternative mechanism—cAMP preservation—that bypasses adrenergic receptors entirely and combines inotropy with vasodilation (inodilation).

1992 • Levosimendan Introduced

Levosimendan, a calcium sensitizer, was developed in Finland. Unlike traditional inotropes that raise intracellular calcium, it enhances the sensitivity of troponin C to existing calcium, representing a paradigm shift in inotropic strategy.

2010s • Omecamtiv Mecarbil & Myosin Activators

Cardiac myosin activators entered clinical trials, directly targeting the sarcomere's motor protein rather than second-messenger signaling. This newest class promises contractility enhancement with minimal arrhythmogenic risk.

The central question that unifies this timeline is deceptively simple: How can we increase the force of myocardial contraction without unacceptably increasing oxygen demand or triggering arrhythmias? Each generation of inotropes has attempted to answer this question by targeting a different node in the excitation-contraction coupling pathway, and understanding those nodes is the key to mastering this drug class.

SECTION 2

Core Principles & Definitions

An inotrope is any agent that alters the force of myocardial contraction. A positive inotrope increases contractility, while a negative inotrope decreases it. Clinical usage of the term 'inotrope' almost always refers to positive inotropes used in the management of acute decompensated heart failure, cardiogenic shock, or low cardiac output states after cardiac surgery. To appreciate how these drugs work, one must first understand the fundamental physiology of excitation-contraction coupling and the central role of intracellular calcium.

Inotropy

The intrinsic ability of the myocardium to develop force independent of preload and afterload. Clinically assessed as dP/dt_max (the maximum rate of pressure rise in the left ventricle during isovolumetric contraction).

Excitation-Contraction Coupling

The cascade linking the cardiac action potential to sarcomere shortening. An action potential opens L-type Ca²⁺ channels → Ca²⁺ triggers ryanodine receptor (RyR) release from the sarcoplasmic reticulum (SR) → Ca²⁺ binds troponin C → actin-myosin cross-bridge cycling.

cAMP–PKA Signaling Axis

β₁-receptor stimulation activates adenylyl cyclase → ↑cAMP → protein kinase A (PKA) phosphorylates L-type Ca²⁺ channels, RyR, and phospholamban, collectively increasing intracellular Ca²⁺ availability and SR reuptake rate (positive lusitropy).

Calcium Sensitization

An alternative mechanism that increases contractility by enhancing the affinity of troponin C for Ca²⁺ rather than raising intracellular Ca²⁺ concentration. This approach theoretically reduces arrhythmia risk and oxygen consumption.

Inodilation

The dual pharmacological effect of increasing cardiac contractility while simultaneously producing peripheral vasodilation. PDE-3 inhibitors (milrinone) and levosimendan exemplify this concept, reducing afterload as they augment output.

✦

KEY TAKEAWAY

Think of the myocardial cell as a concert hall. The cAMP–PKA pathway is like turning up the volume on every speaker (more Ca²⁺ floods in), while calcium sensitization is like tuning the acoustics so the existing sound carries more power. Both make the music louder, but one uses more electricity (oxygen) and risks feedback (arrhythmias), while the other works more efficiently with what's already there.

SECTION 3

Excitation-Contraction Coupling & Inotrope Targets

This diagram maps the five major inotrope classes to their specific targets within the excitation-contraction coupling pathway. β₁ agonists (purple) act at the receptor level; PDE-3 inhibitors (pink) preserve cAMP downstream; calcium sensitizers (amber) target troponin C at the sarcomere; digoxin (cyan) indirectly raises Ca²⁺ via Na⁺/K⁺-ATPase inhibition; and myosin activators (orange) act directly on the contractile machinery.

The diagram above reveals a critical insight: most positive inotropes converge on a single outcome—increasing the concentration of free cytoplasmic Ca²⁺ available to the contractile apparatus. The β₁ agonists and PDE-3 inhibitors both operate through the cAMP–PKA signaling axis, albeit at different points. This shared mechanism explains why combining dobutamine with milrinone can produce additive effects but also compounding toxicities, particularly tachyarrhythmias, since both ultimately flood the cell with calcium. By contrast, levosimendan and omecamtiv mecarbil act downstream of calcium entry, offering contractility enhancement that is at least partially decoupled from the arrhythmogenic consequences of calcium overload.

SECTION 4

Mechanisms of Action — Deep Dive

1. Catecholamines & β₁-Adrenergic Agonists

Dobutamine is the prototypical β₁-selective agonist used clinically for its positive inotropic effect. It binds β₁-adrenergic receptors on cardiomyocytes, activating the stimulatory G-protein (Gₛ), which in turn activates adenylyl cyclase. The resulting increase in intracellular cyclic adenosine monophosphate (cAMP) activates protein kinase A (PKA). PKA phosphorylates three key substrates: the L-type Ca²⁺ channel (increasing Ca²⁺ entry), the ryanodine receptor RyR2 (increasing Ca²⁺ release from the SR), and phospholamban (relieving its inhibition of SERCA2a, thus accelerating Ca²⁺ reuptake and producing a positive lusitropic effect). Epinephrine and norepinephrine also act through this pathway but have additional α₁-mediated vasoconstriction, which raises afterload.

CARDIAC OUTPUT RELATIONSHIP

CO = SV × HR

CO = cardiac output (L/min), SV = stroke volume (mL/beat), HR = heart rate (beats/min). Positive inotropes increase SV by augmenting contractility, and many also increase HR through chronotropic effects, both raising CO.

2. PDE-3 Inhibitors (Milrinone, Inamrinone)

Milrinone inhibits phosphodiesterase type 3, the enzyme responsible for degrading cAMP in cardiomyocytes and vascular smooth muscle. By preventing cAMP breakdown, milrinone achieves the same downstream effects as β₁ stimulation—PKA activation, enhanced Ca²⁺ cycling—but through a receptor-independent mechanism. In vascular smooth muscle, elevated cAMP promotes relaxation, producing systemic and pulmonary vasodilation. This combination of inotropy and vasodilation is termed inodilation and is particularly advantageous in patients with elevated pulmonary vascular resistance, such as those with right ventricular failure or post-cardiac-surgery patients. Because milrinone bypasses the β₁ receptor, it retains efficacy even when receptors are downregulated from chronic catecholamine exposure—a common scenario in advanced heart failure.

3. Cardiac Glycosides (Digoxin)

Digoxin inhibits the Na⁺/K⁺-ATPase on the sarcolemma, leading to a rise in intracellular Na⁺. This elevated Na⁺ reduces the driving force of the Na⁺/Ca²⁺ exchanger (NCX), which normally extrudes Ca²⁺ in exchange for Na⁺ influx. The net effect is intracellular Ca²⁺ accumulation, which enhances contractility. Digoxin also increases vagal tone centrally, slowing the SA and AV nodes—hence its dual utility in heart failure with atrial fibrillation. However, its narrow therapeutic index (therapeutic range 0.5–2.0 ng/mL) makes toxicity a persistent clinical concern, manifesting as arrhythmias, nausea, visual disturbances, and hyperkalemia.

4. Calcium Sensitizers (Levosimendan)

Levosimendan stabilizes the Ca²⁺-bound conformation of troponin C, prolonging the interaction between actin and myosin without increasing intracellular Ca²⁺ concentration. Its binding to troponin C is calcium-dependent; it binds during systole (when Ca²⁺ is high) and dissociates during diastole (when Ca²⁺ is low), thereby preserving diastolic relaxation. Levosimendan also opens ATP-sensitive K⁺ channels in vascular smooth muscle, producing vasodilation, and in mitochondria, contributing to a cardioprotective effect. This multimodal profile makes levosimendan the closest approximation to an 'ideal' inotrope: it improves contractility, reduces afterload, and may offer end-organ protection.

FRANK-STARLING RELATIONSHIP

SV ∝ f(preload, contractility, 1/afterload)

Stroke volume is a function of preload (end-diastolic volume), myocardial contractility (inotropy), and the inverse of afterload (systemic vascular resistance). Positive inotropes shift the Frank-Starling curve upward and to the left, meaning greater SV is achieved at any given preload.

SECTION 5

Classification & Comparative Pharmacology

Inotropes can be classified by their primary mechanism of action, receptor selectivity, hemodynamic profile, and clinical indication. The table below provides a comprehensive comparison of the major agents, enabling rapid identification of the most appropriate drug for a given clinical scenario.

Drug	Class	Mechanism	Hemodynamic Effects	Key Side Effects
Dobutamine	β₁ agonist	↑ cAMP via β₁ → Gₛ → AC	↑ CO, ↑ HR, ↓ SVR (mild)	Tachycardia, arrhythmias, ↑ MVO₂
Epinephrine	α₁ + β₁ + β₂ agonist	↑ cAMP + α₁ vasoconstriction	↑↑ CO, ↑↑ HR, ↑ SVR, ↑ MAP	Arrhythmias, hyperglycemia, lactic acidosis
Norepinephrine	α₁ + β₁ agonist	↑ cAMP + strong α₁ vasoconstriction	↑ MAP, ↑ SVR, ↑ CO (modest)	Tissue ischemia, ↑ afterload
Milrinone	PDE-3 inhibitor	↑ cAMP by ↓ degradation	↑ CO, ↓ SVR, ↓ PVR	Hypotension, thrombocytopenia, arrhythmias
Digoxin	Cardiac glycoside	Na⁺/K⁺-ATPase inhibition → ↑ Ca²⁺	↑ CO (mild), ↓ HR (vagotonic)	Arrhythmias (toxicity), GI symptoms, visual changes
Levosimendan	Ca²⁺ sensitizer + K⁺-ATP opener	Stabilizes Ca²⁺-TnC complex	↑ CO, ↓ SVR, ↓ PVR	Hypotension, headache, hypokalemia

Comparative pharmacology of major inotropic agents

The green curve represents the effect of a positive inotrope, which shifts the Frank-Starling relationship upward, allowing a greater stroke volume at the same preload. The blue curve is the normal heart, and the red curve shows a failing heart operating on a flattened curve with reduced contractile reserve.

💡

CLINICAL PEARL

Norepinephrine is often classified as a vasopressor rather than an inotrope because its predominant clinical effect is α₁-mediated vasoconstriction. However, it does possess β₁-mediated inotropic activity. In practice, norepinephrine is the first-line agent in septic shock (distributive), while dobutamine is added when cardiac output remains inadequate despite restored vascular tone.

SECTION 6

Worked Example — Selecting & Dosing an Inotrope

A 68-year-old male with a history of chronic systolic heart failure (LVEF 20%) presents to the ICU with acute decompensated heart failure. Hemodynamic monitoring via pulmonary artery catheter reveals: cardiac index (CI) = 1.6 L/min/m², PCWP = 28 mmHg, SVR = 1,800 dyn·s/cm⁵, and MAP = 72 mmHg. The patient is on a chronic β-blocker. Determine the most appropriate inotrope and explain the physiological rationale.

Inotrope Selection in Acute Decompensated Heart Failure

1
Step 1 — Identify the Hemodynamic Profile

The patient has a critically low cardiac index (normal ≥ 2.5 L/min/m²), an elevated PCWP (normal 6–12 mmHg, suggesting volume overload/congestion), and elevated SVR (normal 800–1,200 dyn·s/cm⁵, indicating compensatory vasoconstriction). MAP is marginally adequate at 72 mmHg. This profile is consistent with a 'cold and wet' presentation—low perfusion with high filling pressures.

Profile: Low CI, high PCWP, high SVR → 'Cold & Wet'
2
Step 2 — Identify Ideal Hemodynamic Goals

The ideal inotrope for this patient should increase contractility (↑ CI), reduce filling pressures (↓ PCWP via improved forward flow), reduce afterload (↓ SVR to reduce impedance to ejection), and maintain MAP above 65 mmHg. An inodilator—an agent with both inotropic and vasodilatory properties—best fits this profile.

Goal: ↑ CI, ↓ PCWP, ↓ SVR, maintain MAP ≥ 65
3
Step 3 — Consider β-Receptor Downregulation

This patient has chronic heart failure with longstanding neurohumoral activation (elevated endogenous catecholamines) and is on a β-blocker. Both factors predict blunted responsiveness to dobutamine, which requires functional β₁ receptors. Milrinone, a PDE-3 inhibitor, bypasses the receptor entirely and therefore retains efficacy in this setting.

Milrinone preferred: receptor-independent mechanism
4
Step 4 — Dosing & Monitoring

Milrinone is typically initiated with a loading dose of 50 µg/kg IV over 10 minutes (often omitted if MAP is borderline to avoid hypotension), followed by a continuous infusion of 0.375–0.75 µg/kg/min. The dose is renally adjusted because milrinone is ~80% renally excreted. Monitoring should include continuous arterial blood pressure, serial lactate levels (to confirm improved tissue perfusion), and CI trending via PAC. Watch for hypotension (milrinone's vasodilatory effect) and thrombocytopenia with prolonged use.

Milrinone infusion 0.375–0.75 µg/kg/min; omit loading dose if MAP marginal
5
Step 5 — Reassess & Adjust

After 2 hours, repeat hemodynamics show CI improved to 2.4 L/min/m², PCWP decreased to 18 mmHg, SVR reduced to 1,200 dyn·s/cm⁵, and MAP stable at 68 mmHg. The patient demonstrates clinical improvement with warming of extremities and improved urine output. Continue current dose and begin transitioning to oral heart failure therapy (e.g., ACE inhibitor/ARB, β-blocker uptitration) as hemodynamics stabilize.

Hemodynamic improvement confirmed; plan transition to GDMT

SECTION 7

Strengths, Limitations & Clinical Contexts

No single inotrope is universally ideal. Each agent carries a distinct profile of benefits and risks that must be matched to the patient's hemodynamic status, underlying pathology, and comorbid conditions. The table below distills the clinical decision-making framework used in acute care settings.

Agent	Strengths	Limitations	Best Clinical Scenario
Dobutamine	Rapid onset; titratable; well-studied; improves CI with mild afterload reduction	Tachycardia; ↑ MVO₂; tolerance with prolonged use; ineffective with β-blocker or downregulated receptors	Acute cardiogenic shock with adequate blood pressure; stress echo testing
Milrinone	Receptor-independent; ↓ PVR (ideal for RV failure); works despite β-blocker	Hypotension (vasodilation); long half-life (2–3 h); renal adjustment; thrombocytopenia	Post-cardiac surgery with pulmonary hypertension; chronic HF on β-blockers
Digoxin	Oral availability; long duration; vagotonic (↓ HR); reduces HF hospitalizations	Narrow therapeutic index; toxicity potentiated by hypokalemia, renal failure; slow onset IV	Chronic HFrEF with atrial fibrillation; symptom control (not first-line)
Levosimendan	Does not increase intracellular Ca²⁺; preserves diastolic relaxation; active metabolite lasts ~80 h	Hypotension; not available in all countries (not FDA-approved in the US); limited RCT mortality benefit	Acute decompensated HF; perioperative cardiac support (widely used in Europe)
Epinephrine	Potent inotropy + chronotropy + vasoconstriction; ideal for peri-arrest	↑↑ MVO₂; arrhythmias; splanchnic vasoconstriction; lactic acidosis	Cardiac arrest (ACLS); anaphylaxis; refractory cardiogenic shock

Clinical comparison of major inotropic agents

✦

KEY TAKEAWAY

Choosing an inotrope is analogous to selecting a tool from a surgical tray—no single instrument works for every case. The hemodynamic profile (blood pressure, SVR, PVR), the presence of β-receptor downregulation, and the dominant pathophysiology (LV vs. RV failure, systolic vs. diastolic) all inform drug selection. Inotropes are a bridge—sustaining hemodynamics while definitive therapy (revascularization, mechanical support, transplant) is pursued. Long-term inotrope use is associated with increased mortality due to heightened arrhythmia risk and myocardial oxygen demand, which is why guideline-directed medical therapy (GDMT) with neurohormonal blockade remains the cornerstone of chronic heart failure management.

SECTION 8

Connection to Advanced Therapy & Emerging Agents

The development of inotropes continues to evolve toward agents that improve contractility without the calcium-overload penalty. Omecamtiv mecarbil represents the most significant recent advance—a selective cardiac myosin activator that directly accelerates the transition of myosin from a weakly to a strongly bound state on actin, increasing the number of force-generating cross-bridges per cardiac cycle. Critically, it prolongs systolic ejection time rather than increasing the velocity of contraction, achieving greater stroke volume without raising intracellular calcium or increasing heart rate. The GALACTIC-HF trial (2021) demonstrated a modest reduction in heart failure events, though mortality benefit remains uncertain. Understanding traditional inotropes is essential for contextualizing these next-generation agents.

Feature	Traditional Inotropes (cAMP-dependent)	Next-Generation Agents
Primary Target	β₁ receptor, PDE-3, Na⁺/K⁺-ATPase	Troponin C (levosimendan), cardiac myosin (omecamtiv)
Intracellular Ca²⁺	Increased significantly	Unchanged or minimally affected
Heart Rate	Often increased (chronotropy)	Neutral or mildly reduced
MVO₂	Increased (↑ oxygen demand)	Neutral or reduced
Arrhythmia Risk	Significant (Ca²⁺ overload triggers DADs)	Lower (no Ca²⁺ excess)
Long-term Mortality	Increased or neutral in most trials	Under investigation; early signals more favorable

Traditional vs. next-generation inotropes

Beyond pharmacological agents, mechanical circulatory support (MCS) devices—including intra-aortic balloon pumps (IABP), left ventricular assist devices (LVADs), and extracorporeal membrane oxygenation (ECMO)—represent the ultimate 'inotropic' intervention when drug therapy is insufficient. Understanding where each inotrope sits on the escalation ladder from pharmacological support to mechanical support is a core competency in critical-care cardiovascular pharmacology. Students pursuing advanced practice (CRNA, NP, PA) or medical school should also explore the concept of mechanical-pharmacological synergy, in which low-dose inotropes are used alongside MCS to optimize hemodynamics while minimizing drug-related toxicities.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why milrinone retains its inotropic efficacy in a patient with chronic heart failure who has significant β₁-receptor downregulation, whereas dobutamine may fail in the same patient.

Show answer

Dobutamine requires functional β₁-adrenergic receptors to activate the Gₛ–adenylyl cyclase–cAMP cascade. In chronic heart failure, sustained catecholamine exposure leads to receptor internalization and downregulation, reducing the number of surface β₁ receptors available for agonist binding. Milrinone, however, acts downstream of the receptor by inhibiting phosphodiesterase-3, the enzyme that degrades cAMP. Since it does not depend on receptor-mediated cAMP generation, milrinone remains effective even when the upstream receptor is desensitized. This receptor-independent mechanism is a key pharmacological advantage in the chronic heart failure population.

Question 2: BASIC CALCULATION

A 70 kg patient is started on a milrinone infusion at 0.5 µg/kg/min. Calculate the total milrinone dose (in mg) this patient receives over 6 hours.

Show answer

First, calculate the dose rate: 0.5 µg/kg/min × 70 kg = 35 µg/min. Convert to mg/min: 35 µg/min ÷ 1,000 = 0.035 mg/min. Over 6 hours (360 min): 0.035 mg/min × 360 min = 12.6 mg. Therefore, the patient receives a total of 12.6 mg of milrinone over the 6-hour infusion period. This calculation is essential for pharmacy verification, particularly when assessing drug cost and cumulative exposure in patients with impaired renal clearance.

Question 3: INTERMEDIATE

A patient in cardiogenic shock has a MAP of 55 mmHg, CI of 1.4 L/min/m², and SVR of 2,200 dyn·s/cm⁵. Would you initiate dobutamine or norepinephrine first? Justify your answer using hemodynamic principles.

Show answer

In this scenario, the patient's MAP of 55 mmHg is critically low (target ≥ 65 mmHg for adequate organ perfusion). While dobutamine would improve CI, its mild vasodilatory properties could further reduce MAP, potentially worsening tissue perfusion. Norepinephrine should be initiated first because its potent α₁-mediated vasoconstriction will raise MAP toward a safe range, while its β₁ activity provides modest inotropic support. Once MAP is stabilized above 65 mmHg, dobutamine (or milrinone) can be added as a second agent to specifically address the low CI. This reflects the clinical principle that perfusion pressure must be secured before optimizing cardiac output—an approach endorsed by Surviving Sepsis and heart failure guidelines.

Question 4: APPLIED

A post-cardiac-surgery patient develops right ventricular failure with elevated pulmonary vascular resistance (PVR). The surgical team asks for an inotrope recommendation. Which agent is most appropriate, and what is its mechanism of reducing PVR?

Show answer

Milrinone is the most appropriate agent for post-cardiac-surgery right ventricular failure with elevated PVR. As a PDE-3 inhibitor, milrinone increases cAMP in both cardiomyocytes and pulmonary vascular smooth muscle cells. In the heart, elevated cAMP enhances contractility (positive inotropy) and accelerates relaxation (positive lusitropy). In pulmonary vascular smooth muscle, elevated cAMP activates PKA, which phosphorylates myosin light-chain kinase and opens K⁺ channels, causing smooth muscle relaxation and vasodilation. This selective pulmonary vasodilation reduces RV afterload, allowing the failing right ventricle to eject more effectively. The combination of inotropic support and PVR reduction makes milrinone uniquely suited to this clinical scenario. Inhaled milrinone or nitric oxide may be added for targeted pulmonary vasodilation without systemic hypotension.

Question 5: CRITICAL THINKING

All cAMP-dependent inotropes (dobutamine, milrinone) have been associated with increased mortality in long-term use despite improving short-term hemodynamics. Propose a pathophysiological explanation for this paradox, and discuss how newer agents like levosimendan and omecamtiv mecarbil attempt to circumvent this problem.

Show answer

The mortality paradox of cAMP-dependent inotropes arises from the dual-edged nature of intracellular calcium elevation. While acutely beneficial for contractility, chronically elevated cAMP and Ca²⁺ promote several deleterious pathways: (1) increased myocardial oxygen consumption (MVO₂), worsening the supply-demand mismatch in already ischemic myocardium; (2) calcium overload triggers delayed afterdepolarizations (DADs) via spontaneous Ca²⁺ release from the SR, leading to life-threatening ventricular arrhythmias; (3) sustained PKA activation contributes to myocyte apoptosis and adverse remodeling. Levosimendan addresses this by enhancing contractility through calcium sensitization rather than calcium loading—it increases the contractile response to existing calcium levels without raising intracellular Ca²⁺ concentration, thereby avoiding the arrhythmogenic and pro-apoptotic consequences. Omecamtiv mecarbil takes a fundamentally different approach by directly activating cardiac myosin, increasing the number of force-generating cross-bridges without any involvement of second-messenger signaling, calcium cycling, or energy-costly signal transduction. Both strategies decouple the desired effect (increased contractility) from the toxic mechanism (calcium overload), representing a paradigm shift in inotrope design from 'more signal' to 'better machinery.'

SUMMARY

Lesson Summary

Summary

Inotropes are agents that modulate myocardial contractility and are indispensable in managing acute decompensated heart failure, cardiogenic shock, and post-surgical low cardiac output states. The major classes include β₁-adrenergic agonists (dobutamine, epinephrine), PDE-3 inhibitors (milrinone), cardiac glycosides (digoxin), calcium sensitizers (levosimendan), and emerging cardiac myosin activators (omecamtiv mecarbil). Most traditional inotropes operate through the cAMP–PKA signaling axis, ultimately increasing intracellular Ca²⁺ to enhance actin-myosin cross-bridge cycling, but this mechanism carries inherent risks of arrhythmias, increased myocardial oxygen demand, and adverse long-term outcomes.

Clinical selection depends on the patient's hemodynamic profile (MAP, CI, SVR, PVR), receptor status (β-receptor downregulation in chronic HF), and dominant pathophysiology (LV vs. RV failure, need for vasodilation vs. vasoconstriction). Milrinone is favored in β-blocked patients and RV failure with pulmonary hypertension; levosimendan offers the theoretical advantage of avoiding calcium overload; and next-generation agents aim to decouple contractility enhancement from the toxic consequences of second-messenger amplification. All inotropes should be viewed as a hemodynamic bridge while definitive therapy (revascularization, mechanical support, or transplant) is pursued.